DigestRedComo funciona
Red
/
Empresas
Vi
No verificado

ViiV Healthcare

Sobre qué escribimos

CienciaFarmacéuticaIndustriaSaludVIH, SIDA y enfermedades autoinmunes

16 Comunicados de prensa

Ver todos los comunicados de prensa
17/10/2025
Biotecnología
Farmacéutica
VIH, SIDA y enfermedades autoinmunes
Sanidad
Salud
Higiene alimentaria
Medicina - Varios
Industria
ViiV Healthcare announces 96-week data reaffirming Dovato is as effective as Biktarvy in maintaining virological suppression of HIV-1 with significantly less weight gain
Fuente
ViiV Healthcare
Editor
Business Wire
1.00
0
15/10/2025
Sanidad
Gestión empresarial
Farmacéutica
Venta al público/Minorista
VIH, SIDA y enfermedades autoinmunes
Medicina - Varios
Biotecnología
Ciencia
Asistencia a la infancia
Ir de compras
Salud
Industria
Análisis de Mercados
ViiV Healthcare’s CLARITY study shows long-acting cabotegravir more acceptable than lenacapavir injections after a single dose, with 90% preferring cabotegravir
Fuente
ViiV Healthcare
Editor
Business Wire
1.00
0
09/10/2025
Ciencia
VIH, SIDA y enfermedades autoinmunes
Medicina - Varios
Biotecnología
Salud
Farmacéutica
Eventos
Ferias y Congresos
ViiV Healthcare showcases breadth of clinical and real-world evidence at EACS and IDWeek 2025
Fuente
ViiV Healthcare
Editor
Business Wire
1.00
0
14/07/2025
VIH, SIDA y enfermedades autoinmunes
Farmacéutica
Salud
Análisis de Mercados
Industria
ViiV Healthcare data show 89% of treatment-naïve people with HIV choose to switch to long-acting injectable Vocabria + Rekambys from daily pills after achieving rapid viral suppression
Fuente
ViiV Healthcare
Editor
Business Wire
1.00
0
14/07/2025
VIH, SIDA y enfermedades autoinmunes
Farmacéutica
Salud
Análisis de Mercados
Industria
ViiV Healthcare data show 89% of treatment-naïve people with HIV choose to switch to long-acting injectable Vocabria + Rekambys from daily pills after achieving rapid viral suppression
Fuente
ViiV Healthcare
Editor
Business Wire
1.00
0
14/07/2025
VIH, SIDA y enfermedades autoinmunes
Salud
Ciencia
Farmacéutica
Biotecnología
Mercado laboral
Industria
ViiV Healthcare extends voluntary licensing agreement with Medicines Patent Pool to enable access to innovative long-acting injectable HIV treatment
Fuente
ViiV Healthcare
Editor
Business Wire
1.00
0
08/07/2025
Ciencia
VIH, SIDA y enfermedades autoinmunes
Sanidad
Biotecnología
Farmacéutica
Salud
Eventos
Industria
ViiV Healthcare presents new data demonstrating positive real-world impact of its innovative long-acting injectables for HIV at IAS 2025
Fuente
ViiV Healthcare
Editor
Business Wire
1.00
0
12/03/2025
Eventos
Ferias y Congresos
Industria
Biotecnología
VIH, SIDA y enfermedades autoinmunes
Salud
Farmacéutica
ViiV Healthcare announces new implementation study data showing zero cases of HIV with Apretude, the only long-acting injectable approved for HIV PrEP
Fuente
ViiV Healthcare
Editor
Business Wire
1.00
0
12/03/2025
Eventos
Industria
VIH, SIDA y enfermedades autoinmunes
Salud
Higiene alimentaria
Biotecnología
Medicina - Varios
Farmacéutica
ViiV Healthcare’s investigational broadly neutralising antibody - N6LS - successfully maintains viral suppression in long-acting treatment of HIV
Fuente
ViiV Healthcare
Editor
Business Wire
1.00
0
11/03/2025
Eventos
Industria
Ciencia
Biotecnología
Farmacéutica
VIH, SIDA y enfermedades autoinmunes
Sanidad
Salud
ViiV Healthcare showcases leadership in long-acting injectables innovation at CROI 2025 with data on third-generation integrase inhibitor (INSTI) and highly potent capsid inhibitor against HIV-1
Fuente
ViiV Healthcare
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0